Comparisons9 min readUpdated 2025-08-06

    Fridays vs Telehealth Semaglutide

    Fridays vs Telehealth Semaglutide Compare cost, access, support, and fit before choosing a provider.

    Written by Trimi Medical Team. Medically reviewed by Dr. Asad Niazi, MD, MPH. This article covers fridays vs telehealth semaglutide including pricing, medication access, support, and practical guidance.

    Quick links: Tirzepatide treatment, Semaglutide treatment.

    Related Resources

    For more information, explore our guides on Semaglutide, Trimi Pricing Subscription Shipping, Tirzepatide, How It Works.

    You can also browse our Cheapest Tirzepatide Provider 2026, Glp1 Complete Guide, Tirzepatide Vs Semaglutide, Semaglutide Weight Loss Results, Buy Tirzepatide Online, Compounded Semaglutide Vs Brand Name guides for additional context.

    Frequently Asked Questions

    What should I know about fridays vs telehealth semaglutide?

    When researching fridays vs telehealth semaglutide, compare pricing transparency, medication access, support quality, refill convenience, and how well each provider fits your personal health goals. These practical factors matter more than brand reputation alone.

    How does Fridays compare to Trimi?

    The best choice between Fridays and Trimi depends on what you value most: pricing clarity, medication options, clinician support, and how simple the treatment process feels after signup. This is a care-path comparison, not just a medication comparison.

    Which is more affordable, Fridays or Trimi?

    Pricing comparison between Fridays and Trimi should go beyond headline numbers. Compare how understandable the total cost is, what is included in the monthly price, how dose changes affect cost, and whether there are hidden add-on fees.

    What should I compare between weight loss telehealth providers?

    Compare pricing transparency, medication access and options, support model and communication quality, refill flow and convenience, switching friction, and who each service is designed to serve best. These practical factors matter more than brand reputation alone.

    Who might prefer Fridays?

    Some readers may prefer Fridays if they already trust the brand, prefer its specific approach to weight loss treatment, or feel comfortable with its intake and delivery model. Fridays has its own strengths depending on individual priorities.

    Who might prefer Trimi?

    Some readers may prefer Trimi if they want clearer treatment-specific guidance focused on GLP-1 medications, want a more direct comparison path for weight loss options, or care about pricing clarity and simpler decision support.

    How do I decide which provider is right for me?

    Focus on what matters most to you: if brand familiarity matters, consider Fridays. If treatment-specific focus, pricing clarity, and direct GLP-1 guidance matter more, consider Trimi. The best provider fits your priorities and health goals.

    Sources & References

    1. Official provider page: Fridays

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any weight loss treatment. Individual results vary. Both semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 19, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Hims vs Telehealth: side-by-side comparison of pricing, clinician access, pharmacy disclosure, and program structure. Verified 2026 cost data plus how each stacks against Trimi.

    Fridays vs Online: side-by-side comparison of pricing, clinician access, pharmacy disclosure, and program structure. Verified 2026 cost data plus how each stacks against Trimi.

    Found vs Local: side-by-side comparison of pricing, clinician access, pharmacy disclosure, and program structure. Verified 2026 cost data plus how each stacks against Trimi.

    Hims vs Trimi: side-by-side comparison of pricing, clinician access, pharmacy disclosure, and program structure. Verified 2026 cost data plus how each stacks against Trimi.

    Start your GLP-1 journey — from $99/mo

    Get Started